Real-World Experience with Avacopan in ANCA-Associated Vasculitis in Portugal
DOI:
https://doi.org/10.71749/pkj.103Keywords:
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/drug therapy, Avacopan, Glomerular Filtration Rate/drug effects, Kidney Diseases, Portugal, RegistriesAbstract
Introduction: Avacopan, a selective C5a receptor inhibitor, has emerged as a potential corticosteroid-sparing treatment in ANCA-associated vasculitis (AAV). This study aims to evaluate its real-world efficacy and safety in Portuguese patients with active AAV.Methods: We conducted a multicenter retrospective analysis of 15 adult patients with newly diagnosed or relapsing AAV treated with avacopan across nine academic centers in Portugal. Patients received avacopan 30 mg twice daily in conjunction with standard induction and maintenance therapy. Clinical outcomes, including Birmingham Vasculitis Activity Score (BVAS), prednisolone use, renal function, and adverse events, were assessed at 3, 6 and 12 months.
Results: The median patient age was 65 (interquartile range (IQR): 51.5–75.5), and 60% had de novo AAV. Most patients (93.3%) presented with systemic manifestations, and renal involvement was seen in 60%. Median time to start avacopan was 3.45 months. Prednisolone was discontinued in eight patients, with a median time to cessation of 44 days post-avacopan initiation. Median BVAS at baseline, 3 and 12 months was 23 (13-28.5), 2 (2-4.5) and 0 (0-0), respectively. This consistent downward trend indicates effective disease control (p< 0.05). The median estimated glomerular filtration rate (eGFR) at baseline, 3 and 12 months was 15 (9-31), 38 (20-62) and 48 (36.5-83.5), respectively (n=9, p<0.05). Safety was generally acceptable; one patient discontinued avacopan due to reversible hepatotoxicity, and one died from sepsis.
Conclusion: In this real-world Portuguese cohort, avacopan was effective in achieving and maintaining clinical remission in AAV, with a notable steroid-sparing effect. In this sample, we have shown the stability of eGFR in patients with renal involvement, a reduction in disease activity (BVAS improvement), a favorable safety profile, and the potential for use as maintenance monotherapy. These results support avacopan’s potential role in AAV management and warrant further investigation in larger prospective studies.
Downloads
References
Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363:221-32. doi: 10.1056/NEJMoa0909905.
Walsh M, Merkel PA, Peh CA, Szpirt WM, Puéchal X, Fujimoto S, et al. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. N Engl J Med. 2020;382:622-31. doi: 10.1056/NEJMoa1803537.
Furuta S, Nakagomi D, Kobayashi Y, Hiraguri M, Sugiyama T, Amano K, et al. Effect of reduced-dose vs high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: a randomized clinical trial. JAMA. 2021;325:2178-87. doi:10.1001/jama.2021.6615.
Jayne DRW, Merkel PA, Schall TD, Bekker P; ADVOCATE Study Group. Avacopan for the Treatment of ANCA-Associated Vasculitis. N Engl J Med. 2021;384:599-609. doi: 10.1056/NEJMoa2023386. Erratum in: N Engl J Med. 2024;390:388. doi: 10.1056/NEJMX230010.
Food and Drug Administration, fda.gov. FDA approves add-on drug for adults with rare form of blood vessel inflammation [accessed 13 Oct 2021]. Available at: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-add-drug-adults-rare-form-blood-vessel-inflammation.
Health Canada, Canada.ca. Notice: Multiple Additions to the Prescription Drug List; [accessed17 Aug 2022]. Available at: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/prescription-drug-list/notice-changes/multiple-additions-2022-08-17.html.
Robson JC, Grayson PC, Ponte C, Supplai R, Craven A, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. Ann Rheum Dis. 2022;81:315-20. doi: 10.1136/annrheumdis-2021-221795.
Montero-Pastor N, Sánchez-Costa JT, Guerra-Rodriguez M, Sánchez-Alonso F, Moriano C, Loricera J, et al. Development of a web tool to calculate the cumulative dose of glucocorticoids. Reumatol Clin. 2023;19:1-5. doi: 10.1016/j.reumae.2022.11.001.
Zonozi R, Ageel F, Le D, Cortazar FB, Thaker J, Zabala Ramirez MJ, et al. Real-world experience with avacopan in antineutrophil cytoplasmic autoantibody-associated vasculitis. Kidney Int Rep. 2024;9:1783-91. doi: 10.1016/j.ekir.2024.03.022.
McAdoo SP, Medjeral-Thomas N, Gopaluni S, Tanna A, Mansfield N, Galliford J, et al. Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis. Nephrol Dial Transplant. 2019;34:63-73. doi: 10.1093/ndt/gfx378. Erratum in: Nephrol Dial Transplant. 2018;33:899. doi: 10.1093/ndt/gfy075.
Van Leeuwen JR, Bredewold OW, van Dam LS, Werkman SL, Jonker JT, Geelhoed M, et al. Compassionate use of avacopan in difficult-to-treat antineutrophil cytoplasmic antibody-associated vasculitis. Kidney Int Rep. 2021;7:624-8. doi: 10.1016/j.ekir.2021.11.036.
Kubota S, Hanai S, Tanaka-Mabuchi N, Ito R, Nakagomi D. Is it possible to use avacopan alone in the induction of remission in ANCA-associated vasculitis? Rheumatol Adv Pract. 2024;8:rkae100. doi: 10.1093/rap/rkae100.
Van Leeuwen JR, Quartuccio L, Draibe JB, Gunnarson I, Sprangers B, Teng YK. Evaluating Avacopan in the Treatment of ANCA-Associated Vasculitis: Design, Development and Positioning of Therapy. Drug Des Devel Ther. 2025;19:23-37. doi: 10.2147/DDDT5341842.
Odler B, Riedl R, Geetha D, Szpirt WM, Hawley C, Uchida L, et al. The effects of plasma exchange and glucocorticoids on early kidney function among patients with ANCA-associated vasculitis in the PEXIVAS trial. Kidney Int. 2025;107:558-67. doi: 10.1016/j.kint.2024.11.029.
Draibe J, Espigol-Frigolé G, Cid MC, Prados MC, Guillén E, Villacorta J, et al. The real-world use and effectiveness of avacopan in routine practice for the treatment of ANCA vasculitis. First experiences in Spain. Rheumatology. 2025;64:2019-26. doi: 10.1093/rheumatology/keae534.
Casal Moura M, Crowson CS, Specks U, Warrington KJ, Zand L, Sethi S, Fervenza FC. PLEX in AAV-GN: insights from the meta-analysis results and impact on remission induction treatment recommendations. Clin Kidney J. 2022;16:432-6. doi: 10.1093/ckj/sfac221.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Sofia Oliveira Correia, Ivo Laranjinha, Estela Nogueira, Anita Cunha, Catarina Tenazinha, Helena Pinto, Inês Ferreira, João Fernandes Serodio, José Silvano, Maria João Gonçalves, Miguel Gonçalves, Lídia Teixeira, Vitor Silvestre Teixeira, Alice Lança, António Inácio, Clara Santos, Iolanda Godinho, Raquel Vaz, Teresa Moura Jerónimo, Nuno Afonso
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
